Anteris Technologies Global Corp. Common Stock (AVR)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I keep coming back to Graham's question: what is this business worth on proven numbers? Anteris fails that test today. It is a structural-heart device company with 174 employees and an innovative DurAVR valve, but filed revenue was only $1.9M in fiscal 2025 (the year ended 2025-12-31), down from $2.7M in fiscal 2024 (the year ended 2024-12-31). In fiscal Q2 2026 (the quarter ended 2026-06-30), revenue was $1.0M and net loss was $29.1M; a year earlier, fiscal Q2 2025 (the quarter ended 2025-06-30) had revenue of $618,000 and a net loss of $20.8M. Losses are widening even as sales are barely visible. At the 2026-10-13 close of $6.45, FairStock shows a P/E of -3.31, P/B of 2.50, ROE of -74.65%, ROCE of -42.51%, and FCF yield of -14.0%. Trailing free cash flow is -$88.3M. The Piotroski score is 3/9 and the FairStock score is 20/100. The low D/E of 0.01 and FairStock's Altman Z-Score of 16.62 suggest debt is not the immediate issue, but equity capital is being consumed. The moat is unproven. DurAVR may be differentiated, yet commercial adoption and regulatory success are future events, not current cash flows. With a $628.6M market cap resting on $1.9M of fiscal 2025 revenue, there is no conventional margin of safety. I would call this a venture-style medical device bet, not a Graham bargain.

In plain English: Anteris makes a new kind of heart valve device. The business looks weak today: it sells very little and loses a lot of money. At the recent close of $6.45, the price looks expensive compared with those tiny sales and large losses, so it is mostly a bet on future products rather than current profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer